In contrast, SHP2 has been proposed to play a major tumor suppressive role in hepatocarcinogenesis (Li et al., 2012), in line with the finding that a short tandem repeat polymorphism of PTPN11 (rs199618935, now merged into rs80269561) that leads to increased SHP2 levels confers a decreased risk to develop hepatocellular carcinoma (Zhao et al., 2014). This evidence concerns the gene PTPN11 and neoplasm.